Stockreport

EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema [Yahoo! Finance]

EyePoint, Inc.  (EYPT) 
Last eyepoint, inc. earnings: 3/5 07:00 am Check Earnings Report
PDF AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 – – New preclinical data demonstrates that vorolanib, the active drug in DUR [Read more]